Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure

OBJECTIVE: Previous reports of RAPID-PsA (NCT01087788) demonstrated efficacy and safety of certolizumab pegol (CZP) over 24 weeks in patients with psoriatic arthritis (PsA), including patients with prior antitumour necrosis factor (TNF) therapy. We report efficacy and safety data from a 96-week data...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, P, Deodhar, A, Fleischmann, R, Wollenhaupt, J, Gladman, D, Leszczyński, P, Vitek, P, Turkiewicz, A, Khraishi, M, FitzGerald, O, Landewé, R, de Longueville, M, Hoepken, B, Peterson, L, van der Heijde, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612702/
https://www.ncbi.nlm.nih.gov/pubmed/26509074
http://dx.doi.org/10.1136/rmdopen-2015-000119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612702/
https://www.ncbi.nlm.nih.gov/pubmed/26509074
http://dx.doi.org/10.1136/rmdopen-2015-000119

Ejemplares similares